- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT03025711
Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine (KNOWHER)
Use Of Pertuzumab And Trastuzumab Emtansine In Adult Patients With Her2-Positive Metastatic Or Locally Recurrent Unresectable Breast Cancer
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
This is a retrospective, non-interventional, non-comparative, observational cohort study / registry in the Spain. The study design will reflect real-life clinical management of patients with HER2-positive MBC. Type and frequency of actual patient visits and all evaluations will be done as for routine clinical practice.
The analysis of the efficacy and safety results obtained in patients receiving pertuzumab or TDM1 in those early access systems is of utmost importance. These real-world patients with advanced breast cancer may have different characteristics than those enrolled in clinical trials and clinicians must often extrapolate into therapeutic decisions not fully supported by a robust evidence.
Tanulmány típusa
Beiratkozás (Tényleges)
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Madrid, Spanyolország, 28222
- Puerta de Hierro University Hospital
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Mintavételi módszer
Tanulmányi populáció
Leírás
Inclusion Criteria:
- Adult patients (age ≥ 18 years at enrolment) with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) or Pertuzumab.
- Patients who initiate Trastuzumab emtansine (T-DM1) and Pertuzumab under Spanish compassionate use or early access program.
Exclusion Criteria:
- Given the characteristics of the study there are no exclusion criteria.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
Kohorszok és beavatkozások
Csoport / Kohorsz |
---|
Pertuzumab
Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
|
Trastuzumab emtansine
Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Overall survival.
Időkeret: Through study completion (from date of start of treatment until the date of death from any cause, assessed up to 48 months).
|
The time between the date of start of treatment and the date of death.
For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive
|
Through study completion (from date of start of treatment until the date of death from any cause, assessed up to 48 months).
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Progression free survival.
Időkeret: Through study completion (from date of start of treatment until the date of first documented progression assessed up to 48 months)
|
The time from start of treatment to the date of the first documented tumour progression as determined by the clinician (may be based on clinical examination or radiographic or laboratory features).
|
Through study completion (from date of start of treatment until the date of first documented progression assessed up to 48 months)
|
Best overall response rate
Időkeret: Through study completion, an average of 4 year
|
Response rate is defined as the proportion of patients with complete response (CR) or partial response (PR) based on their best overall response as written in the medical record
|
Through study completion, an average of 4 year
|
Duration of response (DOR)
Időkeret: Through study completion, an average of 4 year
|
The time between the date of first confirmed response to the date of the first documented tumour progression, or death due to any cause, whichever occurs first.
At the time of the analysis, several limitations should be taken into consideration for this retrospective study: DOR is only appraisable if measurable disease and DOR data availability in the medical records (ideally assessed with the RECIST criteria) could be incomplete.
|
Through study completion, an average of 4 year
|
Time to treatment failure
Időkeret: Through study completion (from date of start of treatment until the date of treatment failure, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of treatment failure, assessed up to 48 months)
|
|
Time to Objective Response
Időkeret: Through study completion (from date of start of treatment until the date of the first confirmed response, assessed up to 48 months)
|
The time from start of treatment to the date of the first confirmed response (evaluated for responders only)
|
Through study completion (from date of start of treatment until the date of the first confirmed response, assessed up to 48 months)
|
Time to change treatment
Időkeret: Through study completion (from date of start of treatment until the date of change treatment, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of change treatment, assessed up to 48 months)
|
|
Time to next treatment
Időkeret: Through study completion (from date of start of treatment until the date of start other treatment, assessed up to 48 months)
|
Through study completion (from date of start of treatment until the date of start other treatment, assessed up to 48 months)
|
|
All suspected Grade 3/4/5 adverse reactions
Időkeret: Through study completion, an average of 4 year
|
Through study completion, an average of 4 year
|
|
Adverse events of special interest to anti HER2 Mab (AESI)
Időkeret: Through study completion, an average of 4 year
|
|
Through study completion, an average of 4 year
|
AEs of scientific interest
Időkeret: Through study completion, an average of 4 year
|
|
Through study completion, an average of 4 year
|
Együttműködők és nyomozók
Szponzor
Nyomozók
- Kutatásvezető: Belén Ruiz-Antorán, PhD, Department of Clinical Pharmacology, University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- ML29844
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Mellrák neoplazmák
-
European Association for Endoscopic SurgeryVisszavont
-
Fudan UniversityShanghai Zhongshan Hospital; RenJi Hospital; First Hospital of China Medical University és más munkatársakMég nincs toborzás
-
Institut Paoli-CalmettesBefejezveMÉH NYAJNYAKI NEOPLASMAI | ENDOMETRIÁLIS NEOPLASMSFranciaország